Topic blood cancer

QIAGEN  announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not d more

Immune System Therapeutics Limited (IST) announced it had secured patent protection in Australia for a new method of treating blood cancers that express a target called lambda myeloma antigen (LMA), which was discovered by IST research scientists.  This patent is a significant addition to IST’s grow more

Immune System Therapeutics Limited (IST) announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer. The trial expansion in Australia follows a positive review of safety and efficacy data by an independent Data Monitoring Commi more

Overview: Multiple lines of attack Nature. doi:10.1038/480S34a Author: Duncan Graham-Rowe Researchers are developing new weapons to fight a deadly form of blood cancer. more

Environmental and genomic stresses induce different pathological conditions and one of them is blood cancer. This escalating load of disease with a constant threat to life requires an intensive comprehensive response. For our understanding about the cancer treatment capabilities, novel medicinal pla more

Cancer: The flipside of Notch Nature 473, 7346 (2011). doi:10.1038/473159a Authors: Demetrios Kalaitzidis & Scott A. Armstrong Mutations that lead to increased activity of the Notch signalling pathway are well defined in human cancer more

Millennium Pharmaceuticals, Inc. (Millennium) is a biopharmaceutical company which is engaged in the research, development, and commercialization of medicines for the treatment of cancer in the US and across the globe. In May, 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited. T more

Multiple Myeloma Research Foundation (MMRF) is a bio-pharmaceutical company, based in the US. It is principally engaged in the development of advanced Multiple Myeloma treatments. The company mainly focuses on providing end-to-end solutions to accelerate drug discovery and development targeting mult more